Germany has shifted from relative pricing freedom to a market that is sensitive and influenced by cost-containment policies. But pharma is pressuring the country to change its policy again.
Nathan Jessop
Advertisement
Nathan Jessop is a columnist for Pharmaceutical Technology Europe.
Articles by Nathan Jessop
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
Advertisement
Latest Updated Articles
European Pharma Depressed by German PricingAugust 6th 2012
European Pharma to Surge Ahead Of US?January 1st 2012
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5